Elkfork Partners’s Protara Therapeutics TARA Stock Holding History

Elkfork Partners’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-72	Closed	-$7K	–	1047
2018 Q4	$7K	Buy	+72	New	+$5.08K	﹤0.01%	1008

Other funds holding TARA

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Elkfork Partners's TARA Position: Q1 2019 in Review

Elkfork Partners sold out of Protara Therapeutics (TARA) in Q1 2019, closing a stake of 72 shares — an estimated $7K sold.

Elkfork Partners first reported a position in TARA in Q4 2018 and held it in 1 quarter. The position peaked at $7K in Q4 2018. 14 funds tracked by Wall St. Rank hold TARA as of Q1 2019.

Elkfork Partners reported no remaining Protara Therapeutics position as of Q1 2019 after selling out during the quarter.
Elkfork Partners sold 72 Protara Therapeutics shares in Q1 2019, an estimated $7K.
Elkfork Partners first reported a position in Protara Therapeutics in Q4 2018 and held it in 1 quarter.
Elkfork Partners's Protara Therapeutics position peaked at $7K in Q4 2018.
14 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2019.

Based on Elkfork Partners's 13F filing for Q1 2019, filed 13 May 2019.